Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

麗珠醫藥集團股份有限公司
LIVZON PHARMACEUTICAL GROUP INC.*
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 1513)

POLL RESULTS OF THE ANNUAL GENERAL MEETING FOR THE YEAR 2025, THE 2026 FIRST CLASS MEETING OF A SHAREHOLDERS AND THE 2026 FIRST CLASS MEETING OF H SHAREHOLDERS HELD ON 29 MAY 2026

The board of directors (the "**Board**") of Livzon Pharmaceutical Group Inc.* (麗珠醫藥集團股份有限公司) (the "**Company**") announces that the 2025 Annual General Meeting (the "**AGM**"), the 2026 First A-Share Class Meeting (the "**A-Share Class Meeting**") and the 2026 First H-Share Class Meeting (the "**H-Share Class Meeting**") (collectively, the "**Meetings**") of the Company were held on 29 May 2026 at the Meeting Room on the 6th Floor, Headquarters Building, No. 38 Chuangye North Road, Jinwan District, Zhuhai, Guangdong Province, China. All resolutions proposed at the Meetings as set out in the notices of the Meetings were duly passed by shareholders of the Company by way of poll.

Details of the resolutions considered at the Meetings are set out in the circular of the Company dated 23 April 2026 (the "**Circular**"). Unless otherwise defined, terms used in this announcement shall have the same meanings as defined in the Circular.

As at the record date of the Meetings, the total number of issued shares of the Company was 887,907,171 shares (excluding shares repurchased but not yet cancelled), comprising 588,100,054 A Shares and 299,807,117 H Shares, and the Company had no repurchased but not yet cancelled shares. Accordingly, shareholders (or their proxies) holding an aggregate of 887,907,171 shares of the Company (comprising 588,100,054 A Shares and 299,807,117 H Shares) were entitled to attend the AGM and vote on the resolutions proposed thereat; and shareholders (or their proxies) holding an aggregate of 588,100,054 A Shares and shareholders (or their proxies) holding an aggregate of 299,807,117 H Shares were respectively entitled to attend the A-Share Class Meeting and the H-Share Class Meeting and vote on the resolutions proposed thereat. As at the record date of the Meetings, Directors holding shares of the Company (including their close associates, as defined in the Hong Kong Listing Rules) were required to abstain from voting on resolution no. 7 at the AGM. Accordingly, for the purpose of resolution no. 7, Joincare Pharmaceutical Group Co., Ltd., as an enterprise controlled by Mr. Zhu Baoguo (a Director of the Company), Joincare Pharmaceutical Group Co., Ltd. and its parties acting in concert, Shenzhen Haibin Pharmaceutical Co., Ltd., Guangzhou Begol Trading Holdings Limited, Topsino Industries Limited, as well as Mr. Tang Yanggang (a Director of the Company holding shares of the Company) (including their close associates) (holding an aggregate of 255,858,916 A Shares and 163,364,672 H Shares of the Company) were required to abstain from voting, and shareholders (or their proxies) holding an aggregate of 468,683,583 shares of the Company (comprising 332,241,138 A Shares and 136,442,445 H Shares) were entitled to attend the AGM and vote on resolution no. 7 thereat.

Save as disclosed above, having made all reasonable enquiries, the directors confirm, to the best of their knowledge, information and belief, that no Shareholder is required to abstain from voting on any resolution proposed at the Meetings, and no Shareholder has indicated in the Circular his intention to vote against any resolution or to abstain from voting on any resolution at the Meetings. No Shareholder is required by the Hong Kong Listing Rules to abstain from voting on any resolution at the Meetings.

ATTENDANCE AT THE MEETINGS

(I) Attendance at the AGM:

Set out below are the details of the Shareholders and authorized proxies present at the AGM:

Number of shareholders and proxies present	458
— of which: number of A-Share shareholders and proxies	457
— of which: number of H-Share shareholders and proxies	1
Total number of shares with voting rights (shares)	436,867,402
— of which: total A Shares with voting rights held by A-Share shareholders and proxies (shares)	248,902,032
— of which: total H Shares with voting rights held by H-Share shareholders and proxies (shares)	187,965,370
As a percentage of total shares of the Company (%)	49.2019%
— of which: percentage of total shares with voting rights held by A-Share shareholders and proxies (%)	28.0324%
— of which: percentage of total shares with voting rights held by H-Share shareholders and proxies (%)	21.1695%

(II) Attendance at the A-Share Class Meeting:

The attendance of the A Share Shareholders and their proxies at the A Share Class Meeting is set out below:

Number of A-Share shareholders and proxies present	457
Total number of A Shares with voting rights (shares)	248,902,032
Total number of shares carrying voting rights held by A Shareholders and authorized proxies as a percentage of the total number of A Shares of the Company (%)	42.3231%

(III) Attendance at the H-Share Class Meeting:

The attendance of the H Share Shareholders and their proxies at the H Share Class Meeting is set out below:

Number of H-Share shareholders and proxies present	1
Total number of H Shares with voting rights (shares)	187,989,870
Total number of shares carrying voting rights held by H Shareholders and authorized proxies as a percentage of the total number of H Shares of the Company (%)	62.7036%

POLL RESULTS OF THE RESOLUTIONS PROPOSED AT THE MEETINGS

(I) Poll results at the AGM are as follows:

(1) Non-cumulative voting

Item	Resolution	Category of Shares	Number of Shares with voting rights held by Shareholders present at the meeting	For		Against		Abstain	
				Number of Shares	Approximate percentage (%) of total number of Shares with voting rights held by Shareholders present at the meeting	Number of Shares	Approximate percentage (%) of total number of Shares with voting rights held by Shareholders present at the meeting	Number of Shares	Approximate percentage (%) of total number of Shares with voting rights held by Shareholders present at the meeting
Ordinary Resolutions									
1	To consider and approve the 2025 Annual Report and Results Announcement of Livzon Pharmaceutical Group Inc.	Total	436,867,402	436,593,976	99.9374%	172,026	0.0394%	101,400	0.0232%
		A Shares	248,902,032	248,661,106	99.9032%	172,026	0.0691%	68,900	0.0277%
		H Shares	187,965,370	187,932,870	99.9827%	0	0.0000%	32,500	0.0173%
2	To consider and approve the Work Report of the Board of Directors of the Company for 2025.	Total	436,867,402	436,514,376	99.9192%	245,926	0.0563%	107,100	0.0245%
		A Shares	248,902,032	248,581,506	99.8712%	245,926	0.0988%	74,600	0.0300%
		H Shares	187,965,370	187,932,870	99.9827%	0	0.0000%	32,500	0.0173%
3	To consider and approve the Financial Settlement Report of the Company for 2025.	Total	436,867,402	436,570,359	99.9320%	183,326	0.0420%	113,717	0.0260%
		A Shares	248,902,032	248,637,489	99.8937%	183,326	0.0737%	81,217	0.0326%
		H Shares	187,965,370	187,932,870	99.9827%	0	0.0000%	32,500	0.0173%

Item	Resolution	Category of Shares	Number of Shares with voting rights held by Shareholders present at the meeting	For		Against		Abstain	
				Number of Shares	Approximate percentage (%) of total number of Shares with voting rights held by Shareholders present at the meeting	Number of Shares	Approximate percentage (%) of total number of Shares with voting rights held by Shareholders present at the meeting	Number of Shares	Approximate percentage (%) of total number of Shares with voting rights held by Shareholders present at the meeting
4	To consider and approve the proposed re-appointment of Grant Thornton (Special General Partnership) as auditors of the Company for 2026 and authorisation of remuneration.	Total	436,867,402	417,372,830	95.5376%	19,385,213	4.4373%	109,359	0.0250%
		A Shares	248,902,032	244,363,407	98.1765%	4,430,966	1.7802%	107,659	0.0433%
		H Shares	187,965,370	173,009,423	92.0432%	14,954,247	7.9559%	1,700	0.0009%
5	To consider and approve the proposed profit distribution plan of the Company for 2025.	Total	436,867,402	436,354,938	99.8827%	468,964	0.1073%	43,500	0.0100%
		A Shares	248,902,032	248,391,268	99.7948%	468,964	0.1884%	41,800	0.0168%
		H Shares	187,965,370	187,963,670	99.9991%	0	0.0000%	1,700	0.0009%
6	To consider and approve the proposed formulation of the "Director Remuneration Management System".	Total	436,867,402	435,789,820	99.7533%	932,591	0.2135%	144,991	0.0332%
		A Shares	248,902,032	247,985,850	99.6319%	772,891	0.3105%	143,291	0.0576%
		H Shares	187,965,370	187,803,970	99.9141%	159,700	0.0850%	1,700	0.0009%
7	To consider and approve the proposed remuneration (allowance) plan for the directors of the 11th Session of the Board for 2026. (Note 1)	Total	35,295,106	34,283,625	97.1342%	865,181	2.4513%	146,300	0.4145%
		A Shares	10,694,408	9,684,627	90.5579%	865,181	8.0900%	144,600	1.3521%
		H Shares	24,600,698	24,598,998	99.9931%	0	0.0000%	1,700	0.0069%
	As votes cast for all the above ordinary resolutions were more than one-half of the valid voting rights of Shareholders (including authorized proxies) present at the AGM, all the above ordinary resolutions were duly passed as ordinary resolutions.								

Item	Resolution	Category of Shares	Number of Shares with voting rights held by Shareholders present at the meeting	For		Against		Abstain	
				Number of Shares	Approximate percentage (%) of total number of Shares with voting rights held by Shareholders present at the meeting	Number of Shares	Approximate percentage (%) of total number of Shares with voting rights held by Shareholders present at the meeting	Number of Shares	Approximate percentage (%) of total number of Shares with voting rights held by Shareholders present at the meeting
8	To consider and approve the proposed amendments to the Articles of Association and the registration of changes with the relevant government authorities.	Total	436,867,402	436,580,534	99.9343%	222,026	0.0508%	64,842	0.0148%
		A Shares	248,902,032	248,616,864	99.8854%	222,026	0.0892%	63,142	0.0254%
		H Shares	187,965,370	187,963,670	99.9991%	0	0.0000%	1,700	0.0009%
9	To consider and approve the credit financing of the Company and the provision of financing guarantees for its subsidiaries.	Total	436,867,402	435,542,127	99.6966%	1,034,533	0.2368%	290,742	0.0666%
		A Shares	248,902,032	248,481,234	99.8309%	291,456	0.1171%	129,342	0.0520%
		H Shares	187,965,370	187,060,893	99.5188%	743,077	0.3953%	161,400	0.0859%
10	To consider and approve the granting of a general mandate to the Board to repurchase H shares of the Company.	Total	436,867,402	435,750,030	99.7442%	1,046,330	0.2395%	71,042	0.0163%
		A Shares	248,902,032	248,304,793	99.7601%	527,897	0.2121%	69,342	0.0279%
		H Shares	187,965,370	187,445,237	99.7233%	518,433	0.2758%	1,700	0.0009%
	As votes cast for all the above special resolutions were more than two-thirds of the valid voting rights of Shareholders (including authorized proxies) present at the AGM, all the above special resolutions were duly passed as special resolutions at the AGM.								

(2) Cumulative voting

No.	Resolution	Category of Shares	Number of shares carrying cumulative votes cast in favour	Percentage of votes cast in favour to the total number of valid votes represented at the annual general meeting (approximate %)	Whether elected
11. To consider and approve, item by item, the re-election of non-independent directors of the 12th Session of the Board.					
11.1	To consider and approve the re-election of Mr. Zhu Baoguo as a non-executive director of the 12th Session of the Board.	Total	430,552,858	98.5546%	**Yes**
		A Shares	243,836,681	97.9649%	
		H Shares	186,716,177	99.3354%	
11.2	To consider and approve the re-election of Mr. Tang Yanggang as an executive director of the 12th Session of the Board.	Total	424,598,248	97.1916%	**Yes**
		A Shares	243,446,059	97.8080%	
		H Shares	181,152,189	96.3753%	
11.3	To consider and approve the re-election of Mr. Lin Nanqi as a non-executive director of the 12th Session of the Board.	Total	430,501,933	98.5429%	**Yes**
		A Shares	243,709,694	97.9139%	
		H Shares	186,792,239	99.3759%	
11.4	To consider and approve the re-election of Mr. Qiu Qingfeng as a non-executive director of the 12th Session of the Board.	Total	430,509,943	98.5448%	**Yes**
		A Shares	243,717,704	97.9171%	
		H Shares	186,792,239	99.3759%	
12. To consider and approve, item by item, the re-election of independent directors of the 12th Session of the Board.					
12.1	To consider and approve the re-election of Mr. Luo Huiyuan as an independent non-executive director of the 12th Session of the Board.	Total	434,000,265	99.3437%	**Yes**
		A Shares	247,258,494	99.3397%	
		H Shares	186,741,771	99.3490%	
12.2	To consider and approve the re-election of Ms. Cui Lijie as an independent non-executive director of the 12th Session of the Board.	Total	433,220,289	99.1652%	**Yes**
		A Shares	246,400,618	98.9950%	
		H Shares	186,819,671	99.3905%	

No.	Resolution	Category of Shares	Number of shares carrying cumulative votes cast in favour	Percentage of votes cast in favour to the total number of valid votes represented at the annual general meeting (approximate %)	Whether elected
12.3	To consider and approve the re-election of Ms. Wang Zhiyao as an independent non-executive director of the 12th Session of the Board.	Total	434,316,258	99.4160%	**Yes**
		A Shares	246,352,587	98.9757%	
		H Shares	187,963,671	99.9991%	
13. To consider and approve, item by item, the proposed appointment of executive director and independent non-executive director of the 12th Session of the Board.					
13.1	To consider and approve the proposed appointment of Mr. Liu Daping as an executive director of the 12th Session of the Board.	Total	432,543,210	99.0102%	**Yes**
		A Shares	245,674,671	98.7034%	
		H Shares	186,868,539	99.4165%	
13.2	To consider and approve the proposed appointment of Ms. Kang Li as an independent non-executive director of the 12th Session of the Board.	Total	434,414,457	99.4385%	**Yes**
		A Shares	246,450,786	99.0152%	
		H Shares	187,963,671	99.9991%	
	As votes obtained for all the above ordinary resolutions were more than one-half of the valid voting rights of Shareholders (including authorised proxies) present at the AGM, all the above ordinary resolutions were duly passed as ordinary resolutions.				

Notes:

1. The total number of shares voting in favour of resolution no. 7 at the 2025 AGM was 187,963,670, among which the votes carried by the 163,364,672 H Shares held by Topsino Industries Limited were cast due to an oversight. As Topsino Industries Limited was required to abstain from voting pursuant to the Hong Kong Listing Rules, the votes carried by the aforementioned 163,364,672 H Shares held by Topsino Industries Limited will not be counted. In this regard, the aforementioned voting results in favour of resolution no. 7 do not include the votes carried by the said 163,364,672 H Shares.

(II) Poll results at the A Share Class Meeting are as follows:

Item	Resolution	Category of Shares	Number of Shares with voting rights held by Shareholders present at the meeting	For		Against		Abstain	
				Number of Shares	Approximate percentage (%) of total number of Shares with voting rights held by Shareholders present at the meeting	Number of Shares	Approximate percentage (%) of total number of Shares with voting rights held by Shareholders present at the meeting	Number of Shares	Approximate percentage (%) of total number of Shares with voting rights held by Shareholders present at the meeting
Special Resolution									
1	To consider and approve the granting of a general mandate to the Board to repurchase H shares of the Company.	A Shares	248,902,032	248,304,793	99.7601%	527,897	0.2121%	69,342	0.0279%
	As votes cast for the above special resolution were more than two-thirds of the valid voting rights of A Shareholders (including authorized proxies) present at the A Share Class Meeting, the above special resolution was duly passed as a special resolution at the A Share Class Meeting.								

(III) Poll results at the H Share Class Meeting are as follows:

Item	Resolution	Category of Shares	Number of Shares with voting rights held by Shareholders present at the meeting	For		Against		Abstain	
				Number of Shares	Approximate percentage (%) of total number of Shares with voting rights held by Shareholders present at the meeting	Number of Shares	Approximate percentage (%) of total number of Shares with voting rights held by Shareholders present at the meeting	Number of Shares	Approximate percentage (%) of total number of Shares with voting rights held by Shareholders present at the meeting
Special Resolution									
1	To consider and approve the granting of a general mandate to the Board to repurchase H shares of the Company.	H Shares	187,989,870	187,469,737	99.7233%	518,433	0.2758%	1,700	0.0009%
	As votes cast for the above special resolution were more than two-thirds of the valid voting rights of H Shareholders (including authorised proxies) present at the H Share Class Meeting, the above special resolution was duly passed as a special resolution at the H Share Class Meeting.								

Grant Thornton (Special General Partnership) acted as the scrutineer for the vote-taking at the Meetings. Guangdong Chongli Law Firm (廣東崇立律師事務所), the Company's PRC legal adviser, and two shareholder representatives jointly acted as the scrutineers of the poll at the Meetings.

LEGAL OPINION ISSUED BY LAWYERS

Delegated lawyers from Guangdong Chongli Law Firm witnessed the Meetings and issued the "Legal Opinion of Guangdong Chongli Law Firm in relation to the 2025 Annual General Meeting, the 2026 First Class Meeting of A Shareholders and the 2026 First Class Meeting of H Shareholders of Livzon Pharmaceutical Group Inc.", certifying that: "The convening and procedures of the Meetings comply with the requirements of laws, regulations and Articles of Association, the qualification of persons present at the Meetings, the qualification of the convenors and the voting procedures of the Meetings are lawful and valid, and the results of the resolutions voted at the Meetings are lawful and valid".

SPECIAL NOTICE

There was neither objection to the proposed resolutions of the Meetings, nor changes to the resolutions of the previous general meetings at the Meetings.voted at the Meetings are lawful and valid".

ATTENDANCE RECORD OF THE DIRECTORS

All directors attended the Meetings in person or by electronic means.

CASH DIVIDEND

The Meetings has approved to distribute cash dividend of RMB14.30 (tax inclusive) for every 10 shares to all Shareholders, based on the total number of shares as at the equity registration date for implementation of the 2025 profit distribution plan (excluding shares repurchased but not yet cancelled). No bonus shares will be distributed and no capitalisation of capital reserve will be carried out.

The cash dividend will be paid to Shareholders whose names are on the register of the Shareholders of the Company on Wednesday, 17 June 2026. The proposed cash dividend will be denominated in RMB and paid in RMB to A Shareholders and in Hong Kong dollars to H Shareholders. The exchange rate for payment of dividends in Hong Kong dollars shall be based on the middle rate of RMB against Hong Kong dollars announced by the People's Bank of China on the date of the AGM (Friday, 29 May 2026), which is HKD1.00 to RMB0.8703. Accordingly, the cash dividend per 10 H shares of the Company will be approximately HKD16.43 (tax inclusive).

Dividend cheques will be dispatched to H Shareholders entitled to the dividend by ordinary post on or before Monday, 13 July 2026 at their own risk. The record date for determining the entitlement of H Shareholders to receive the proposed cash dividend will be Wednesday, 17 June 2026. H Shareholders who are not yet registered must lodge all transfers of shares accompanied by the relevant share certificates with the Company's H Share Registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong for registration no later than 4:30 p.m. on Wednesday, 17 June 2026.

Pursuant to the Enterprise Income Tax Law of the People's Republic of China (the "**Enterprise Income Tax Law**") and the Rules for the Implementation of the Enterprise Income Tax Law of the People's Republic of China (the "**Implementation Rules**") which have been effective since 1 January 2008, and the Notice of the State Administration of Taxation on Issues Relevant to the Withholding of Enterprise Income Tax on Dividends Paid by PRC Resident Enterprises to Offshore Non-resident Enterprise Holders of H Shares (Guo Shui Han [2008] No. 897) issued by the State Administration of Taxation on 6 November 2008, the Company is obliged to withhold enterprise income tax at the rate of 10% when distributing dividends to non-resident enterprise Shareholders whose names appear on the register of H Shareholders of the Company. H shares registered in the name of non-individual Shareholders, including those registered in the name of HKSCC Nominees Limited, other nominees or trustees, or other organisations and groups, will be deemed as shares held by non-resident enterprise Shareholders and the relevant dividends will be subject to deduction of enterprise income tax. Non-resident enterprise Shareholders may apply for a tax refund (if applicable) after receiving the dividends in accordance with relevant tax treaty (arrangement) and other applicable tax laws and regulations. Pursuant to the Notice on Certain Issues Concerning the Policies of Individual Income Tax (Cai Shui Zi [1994] No. 020) issued by the Ministry of Finance and the State Administration of Taxation on 13 May 1994, dividends paid by foreign-invested enterprises to foreign individual investors are temporarily exempt from individual income tax. As the Company is a foreign-invested enterprise, the Company will not withhold individual income tax on behalf of foreign individual Shareholders whose names appear on the register of H Shareholders of the Company when paying dividends.

Pursuant to the Notice of the Ministry of Finance, the State Administration of Taxation, and the China Securities Regulatory Commission on Taxation Policies concerning the Pilot Program of an Interconnection Mechanism for Transactions in the Shenzhen and Hong Kong Stock Markets (Cai Shui [2016] No. 127), (i) for dividends received by mainland individual investors from investment in H shares listed on the Stock Exchange of Hong Kong Limited through the Shenzhen-Hong Kong Stock Connect, the Company shall apply to China Securities Depository and Clearing Corporation Limited ("**CSDCC**") for a list of mainland individual investors from CSDCC, and withhold individual income tax on their behalf at the rate of 20%. Dividends received by mainland securities investment funds from investment in H shares listed on the Stock Exchange through the Shenzhen-Hong Kong Stock Connect shall be subject to individual income tax in accordance with the above provisions; (ii) for dividends received by mainland enterprise investors from investment in H shares listed on the Stock Exchange through the Shenzhen-Hong Kong Stock Connect, such dividends shall be included in their aggregate income and subject to enterprise income tax in accordance with the law. Where a mainland resident enterprise has continuously held H shares for 12 months or more, the dividends received shall be exempt from enterprise income tax in accordance with the law. The Company shall apply to CSDCC for a list of mainland enterprise investors from CSDCC and will not withhold dividend income tax on mainland enterprise investors' behalf; such taxes shall be self-declared and paid by the enterprises themselves.

The record date, method and time for payment of cash dividends to A Shareholders will be separately announced on the website of Shenzhen Stock Exchange.

By order of the Board
Livzon Pharmaceutical Group Inc.*
麗珠醫藥集團股份有限公司
Liu Ning
Company Secretary

Zhuhai, China
29 May 2026

As at the date of this announcement, the executive directors of the Company are Mr. Liu Daping (President) and Mr. Tang Yanggang (Vice Chairman); the non-executive directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Lin Nanqi and Mr. Qiu Qingfeng; the employee representative director of the Company is Ms. Ran Yongmei; and the independent non-executive directors of the Company are Mr. Luo Huiyuan, Ms. Cui Lijie, Ms. Wang Zhiyao and Ms. Kang Li.

* *For identification purpose only*